ノバルティス、腎不全治療薬のRegulus Therapeuticsを買収へ スイスの製薬大手ノバルティスが、腎疾患に特化したバイオ医薬品企業Regulus Therapeutics社を買収することに合意。ADPKD治療薬の開発が期待される。

ノバルティス、腎不全治療薬のRegulus Therapeuticsを買収へ #ノバルティス #腎不全 #Regulus_Therapeutics

スイスの製薬大手ノバルティスが、腎疾患に特化したバイオ医薬品企業Regulus Therapeutics社を買収することに合意。ADPKD治療薬の開発が期待される。

Regulus Therapeutics Awarded Acquisition by Novartis Following Positive Drug Trial Results Regulus Therapeutics has secured an agreement with Novartis valued at $1.7 billion, as they report promising Phase 1b results for their ADPKD drug, farabursen.

Regulus Therapeutics Awarded Acquisition by Novartis Following Positive Drug Trial Results #USA #San_Diego #Regulus_Therapeutics #Novartis #farabursen

Monteverde & Associates Investigates Proposed Merger of Regulus Therapeutics with Novartis Monteverde & Associates PC is looking into the merger between Regulus Therapeutics Inc. and Novartis AG. This action comes amidst shareholder concerns over the deal's terms.

Monteverde & Associates Investigates Proposed Merger of Regulus Therapeutics with Novartis #United_States #New_York #Monteverde_Associates #Merger_Investigation #Regulus_Therapeutics

Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion Regulus Therapeutics has announced its acquisition by Novartis for $7.00 per share, potentially totaling $1.7 billion with contingent rights.

Regulus Therapeutics to Be Acquired by Novartis AG for Up to $1.7 Billion #USA #San_Diego #Regulus_Therapeutics #farabursen #Novartis_AG

Regulus Therapeutics Celebrates Positive Trial Results for Farabursen in ADPKD Treatment Regulus Therapeutics has announced positive results from its Phase 1b trial for Farabursen, a promising treatment for ADPKD. This breakthrough demonstrates significant progress in managing this condition.

Regulus Therapeutics Celebrates Positive Trial Results for Farabursen in ADPKD Treatment #United_States #San_Diego #Regulus_Therapeutics #farabursen #ADPKD

Regulus Therapeutics Releases Q4 2024 Financial Report and Key Developments Regulus Therapeutics Inc. recently announced its financial results for Q4 2024, highlighting progress in its groundbreaking clinical trials for ADPKD treatments.

Regulus Therapeutics Releases Q4 2024 Financial Report and Key Developments #USA #San_Diego #Regulus_Therapeutics #farabursen #ADPKD

Regulus Therapeutics Set to Provide Insights at Leerink Partners Conference Focused on Innovative Medicines Regulus Therapeutics Inc. will feature key management insights at the upcoming Leerink Partners 2025 Global Healthcare Conference, discussing innovative microRNA-targeted therapies.

Regulus Therapeutics Set to Provide Insights at Leerink Partners Conference Focused on Innovative Medicines #United_States #San_Diego #biotechnology #Regulus_Therapeutics #microRNA

Regulus Therapeutics to Showcase Innovations at Annual Oppenheimer Conference Join Regulus Therapeutics as they present their progress and innovative medicines at the Oppenheimer Annual Healthcare Life Sciences Conference on February 11.

Regulus Therapeutics to Showcase Innovations at Annual Oppenheimer Conference #United_States #San_Diego #Regulus_Therapeutics #microRNAs

Regulus Therapeutics Reports Promising Outcomes in ADPKD Clinical Trials with Farabursen Regulus Therapeutics reveals positive interim data from its Phase 1b trial for ADPKD treatment with farabursen, aligning with FDA for next steps.

Regulus Therapeutics Reports Promising Outcomes in ADPKD Clinical Trials with Farabursen #USA #San_Diego #Regulus_Therapeutics #farabursen #ADPKD

Regulus Therapeutics Set to Engage Investors at Health Conference Events in December 2024 Regulus Therapeutics will be participating in notable healthcare investment conferences in December 2024. Engage with their innovative pipeline and future goals.

Regulus Therapeutics Set to Engage Investors at Health Conference Events in December 2024 #United_States #San_Diego #biopharmaceuticals #Regulus_Therapeutics #Healthcare_Conferences